Azithromycin Treatment Alters Gene Expression in Inflammatory, Lipid Metabolism, and Cell Cycle Pathways in Well-Differentiated Human Airway Epithelia by Ribeiro, Carla Maria P. et al.
Azithromycin Treatment Alters Gene Expression in
Inflammatory, Lipid Metabolism, and Cell Cycle Pathways
in Well-Differentiated Human Airway Epithelia
Carla Maria P. Ribeiro
1,2*, Harry Hurd
3, Yichao Wu
3¤, Mary E. B. Martino
1, Lisa Jones
1, Brian Brighton
1,
Richard C. Boucher
1,2, Wanda K. O’Neal
1,2
1Cystic Fibrosis Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United State of America, 2Department of Medicine, The University of
North Carolina at Chapel Hill, Chapel Hill, North Carolina, United State of America, 3Department of Statistics, The University of North Carolina at Chapel Hill, Chapel Hill,
North Carolina, United State of America
Abstract
Prolonged macrolide antibiotic therapy at low doses improves clinical outcome in patients affected with diffuse
panbronchiolitis and cystic fibrosis. Consensus is building that the therapeutic effects are due to anti-inflammatory, rather
than anti-microbial activities, but the mode of action is likely complex. To gain insights into how the macrolide azithromycin
(AZT) modulates inflammatory responses in airways, well-differentiated primary cultures of human airway epithelia were
exposed to AZT alone, an inflammatory stimulus consisting of soluble factors from cystic fibrosis airways, or AZT followed by
the inflammatory stimulus. RNA microarrays were conducted to identify global and specific gene expression changes.
Analysis of gene expression changes revealed that the AZT treatment alone altered the gene profile of the cells, primarily by
significantly increasing the expression of lipid/cholesterol genes and decreasing the expression of cell cycle/mitosis genes.
The increase in cholesterol biosynthetic genes was confirmed by increased filipin staining, an index of free cholesterol, after
AZT treatment. AZT also affected genes with inflammatory annotations, but the effect was variable (both up- and down-
regulation) and gene specific. AZT pretreatment prevented the up-regulation of some genes, such as MUC5AC and MMP9,
triggered by the inflammatory stimulus, but the up-regulation of other inflammatory genes, e.g., cytokines and chemokines,
such as interleukin-8, was not affected. On the other hand, HLA genes were increased by AZT. Notably, secreted IL-8 protein
levels did not reflect mRNA levels, and were, in fact, higher after AZT pretreatment in cultures exposed to the inflammatory
stimulus, suggesting that AZT can affect inflammatory pathways other than by altering gene expression. These findings
suggest that the specific effects of AZT on inflamed and non-inflamed airway epithelia are likely relevant to its clinical
activity, and their apparent complexity may help explain the diverse immunomodulatory roles of macrolides.
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Introduction
Prolonged macrolide antibiotic therapy at low doses improves
clinical outcome in patients affected with diffuse panbronchiolitis
(DPB) and cystic fibrosis (CF), lethal conditions characterized by
chronic pulmonary Pseudomonas aeruginosa infections, diffuse
inflammation, and airways obstruction [1,2]. These drugs are also
being used to treat patients with other inflammatory lung
conditions, such as sinusitis, chronic obstructive pulmonary
disease, asthma, and bronchiectasis [3]. Both antimicrobial [4,5]
and immunomodulatory activities [6–17] are associated with
macrolide treatment. While antimicrobial activity is one aspect
likely contributing to the clinical outcome, the immunomodulatory
effects are becoming increasingly recognized as critical to the
mode of action of these drugs for the treatment of pulmonary
diseases as well as inflammatory diseases in other organs, such as
inflammatory bowel disease, arthritis, and psoriasis [3].
Whereas the antimicrobial activity of macrolides is known to
result primarily from inhibition of RNA-dependent protein
synthesis in susceptible microorganisms [18], the mechanism of
action concerning immunomodulation is not entirely clear. For
example, macrolide treatment was shown to decrease the levels of
interleukin 8 (IL-8) and/or IL-1b in bronchoalveolar lavage fluid
from DPB and bronchiolitis obliterans patients [6]. Other studies
have reported reduced levels of pro-inflammatory cytokines
triggered by P. aeruginosa challenges or loss of CFTR in murine
lungs [7], reduced production of cytokines by airway epithelia [8–
10], reduced neutrophil influx, chemotaxis and number [7,8,11–
13], inhibition of airway epithelia-mediated neutrophil survival
[14], and increased phagocytosis of apoptotic bronchial epithelial
cells by alveolar macrophages [17]. At a gene expression level,
macrolides have been reported to reduce induction of mucin 5AC
(MUC5AC) synthesis after inflammatory stimuli [19,20] and to
decrease the expression of matrix metallopeptidase 9 (MMP9)
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5806[21,22]. The understanding of macrolide action is complicated by
other findings suggesting that the macrolide azithromycin (AZT)
may actually exhibit some pro-inflammatory features, such as
acute stimulation of neutrophil degranulation and enzyme release,
increased phagocytosis-associated oxidative burst, and increased
serum IL-1b [16].
To gain new insights into the mode of action of AZT in airways,
we evaluated its effect on gene expression in well-differentiated
primary human bronchial epithelial (HBE) cultures using RNA
expression microarrays and measurements of secreted IL-8. Based
upon published reports of immunomodulatory properties, we
hypothesized that AZT would blunt the pro-inflammatory
response induced by exposure of HBE cultures to a potent
inflammatory stimulus, supernatant of mucopurulent material
(SMM) from CF airways [23,24]. Our findings highlight the
complex nature of the AZT effect on airway cells, which involves
up-regulation of lipid/cholesterol biosynthetic pathways, suppres-
sion of cell division pathways, and specific modulation of
inflammatory genes, including down-regulation of mucin produc-
tion. Additionally, we demonstrate that mRNA levels of IL-8 are
not correlated to secreted protein levels, adding additional
complexity to the effect of AZT on the modulation of
inflammatory responses.
Methods
Cell culture
Human bronchial epithelial (HBE) cells were provided by the
Tissue Core of the University of North Carolina CF Center under
the auspices of protocols approved by the Institutional Committee
on the Protection of the Rights of Human Subjects. Cells were
harvested by enzymatic digestion from portions of main stem or
lumbar bronchi, cultured, and studied as well-differentiated
primary cultures maintained at an air-liquid surface interface as
previously described [23,24].
Supernatant of mucopurulent material (SMM) from CF
airways
Mucopurulent material was harvested from the airway lumens
of excised human CF lungs infected with Pseudomonas aeruginosa at
the time of transplant and provided by the Tissue Core of the
University of North Carolina CF Center as previously described
[23,24]. This material was centrifuged at 100,000 rpm (60 min,
4uC), the supernatant filtered through a 0.2 mm filter and frozen at
280uC. To induce airway epithelial inflammation, the mucosal
surfaces of well-differentiated HBE cultures were exposed to 30 ml
SMM for the indicated times in the Figures. 30 ml PBS were used
as a control for SMM as previously reported [23,24].
Azithromycin treatment
AZT (Pfizer) was freshly added (1:1000 dilution from frozen
stocks kept in 280uC) daily and continuously applied to the serosal
compartment, in the absence or presence of mucosal exposure to
30 ml PBS or SMM, throughout the course of the studies. The
concentrations of AZT used in this study are in agreement with
previous pharmacokinetic studies of long-term administration of
AZT (500 mg per day) in CF patients showing that the
concentration of AZT in sputum ranged from 12 to 53 mg/ml
and was still detectable at concentrations in the range of 4 to
27 mg/ml 10 days after the last dose [25].
RNA microarrays
The microarray experiments were performed according to the
MIAME guidelines, and the data from the experiments were
deposited in a publicly accessible database (ftp://ftp.ncbi.nih.gov/
pub/geo/DATA/supplementary/series/; series record GSE10592).
The experimental protocol for these studies is depicted in Table 1.
RNA harvested at different time points from 4 individual codes of
HBE treated withPBS,SMMor AZT,orpretreated withAZT prior
to mucosal exposure to SMM, was hybridized to human Affymetrix
U133 Plus 2.0 arrays. Hybridizations were conducted according
to standard protocols by the University of North Carolina
Genomics Analysis Core. Details of the statistical analyses are
found in Supporting Information (Methods S1). Briefly,
expression levels were estimated using GCRMA [26]. The
local-pooled-error method (LPE) was used for comparisons of
selected treatment pairs and the z-score produced by LPE was
used for selecting probesets with significantly different gene
expression. Probesets ranked by z-scores were used to determine
gene ontology (GO) groups that were over-represented in the
differentially regulated gene lists using hypergeometric probabil-
ities, using a method specifically developed by Harry Hurd (see
Supporting Information, Methods S1, for further documenta-
tion). Hypergeometric probabilities for each of the significant
gene ontology classifications listed for the top probesets up-
regulated or down-regulated by the various treatments are
shown in Multi-Gene Ontology Matrix (MGM) Tables (Sup-
porting Information, Table S6). Hierarchical clustering was used
as a complementary method. Clustering was limited to only
differentially expressed genes as described in the Supporting
Information (Methods S1). Further analysis of the data was
carried out using Ingenuity Pathways Analysis
TM software
available through a license to the University of North Carolina
Lineberger Cancer Center (Ingenuity Systems, Inc., Redwood
City, CA). When the software is utilized, the specific parameters
used for the network visualized are presented in the figure
legend.
Mevastatin treatment
Mevastatin (Fluka) was used to inhibit the activity of 3-hydroxy-
3-methylglutaryl-CoA reductase, which mediates cholesterol
biosynthesis. Mevastatin was serosally added daily at a concen-
tration of 50 mM throughout the course of the tudies, in the
Table 1. Experimental conditions utilized in the microarray
studies.
Treatment Name (N) Treatment Description
T0 (3) No treatment, time 0 control
PBS 6 hr (4) PBS-exposed, harvested at 6 hr
PBS 24 hr (4) PBS-exposed, harvested at 24 hr
AZT 6 hr (3) AZT-treated, harvested at 6 hr
AZT 24 hr (4) AZT-treated, harvested at 24 hr
AZT 48 hr (3) AZT-treated, harvested at 48 hr
SMM 6 hr (4) SMM-exposed, harvested at 6 hr
SMM 24 hr (3) SMM-exposed, harvested at 24 hr
AZT 48 hr+SMM 6 hr (3) AZT-treated for 48 hr; SMM-exposed during last 6 hrs
AZT 72 hr+SMM 24 hr (3) AZT-treated for 72 hr; SMM-exposed during last 24 hrs
PBS: 30 ml mucosal phosphate-buffered saline; AZT: 30 mg/ml serosal
azithromycin. SMM: 30 ml mucosal supernatant from mucopurulent material
from CF airways. N=number of arrays from 4 different human HBE codes that
were used for subsequent analyzes.
doi:10.1371/journal.pone.0005806.t001
Azithromycin and Airways
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and/or serosal exposure to 30 mg/ml AZT.
MUC5AC staining
Immunocytochemistry of MUC5AC was performed according
to standard techniques, utilizing a mouse monoclonal primary
antibody (1:1,000 dilution; Abcam) and an immunoperoxidase
detection system, which contains mouse IgG (VECTASTAIN,
Vector Laboratories).
Real-time quantitative RT-PCR
200 ng of the RNA from HBE cultures treated as described in
the figure legends was reverse transcribed using Superscript II
reverse transcriptase (Invitrogen). Quantitative real-time PCR was
performed using 100 ng of cDNA, Taqman primers and a FAM
labeled Taqman probe for MUC5AC (Hs01365601_m1) and
SREBF (Hs01088691_m1) (Applied Biosystems) on a 7500 Fast
Real-Time PCR system (Applied Biosystems). Data were normal-
ized to 18S expression according to the method of Pfaff [27].
IL-8 secretion
IL-8 secretion into the serosal media was assessed at different
time points in cultures treated with vehicle or AZT alone, or
mucosally exposed to 30 ml PBS or SMM following the AZT
pretreatment. The serosal media were freshly added and collected
daily for IL-8 determination. IL-8 was measured by ELISA (R&D
Systems) in duplicate as previously described [24].
Filipin staining
Filipin staining was performed according to a slight modification
of the method of White et al [28]. Briefly, following the different
treatments, HBE cultures were serosally and mucosally rinsed three
times with PBS, fixed with 4% paraformaldehyde as previously
reported [23,24], rinsed three times with PBS and incubated with
0.05 mg/ml filipin (Sigma) in PBS for 60 min on a shaker in the
dark. Cultures were rinsed in PBS and filipin fluorescence intensity
studied by laser confocal microscopy in the X-Y scanning mode
(Leica, model TCS 4D; PL APO 636/1.20 mm water lens) and
quantified as reported in previous studies [23,24,29].
Statistical analysis
Data in bar graphs represent the mean6SEM from at least 3
experiments. Where appropriate, data were analyzed by two-way
analysis of variance (ANOVA) and statistical significance was
defined with p,0.05.
Results
Microarray studies
Microarray experiments were performed to evaluate global
effects of AZT, with and without inflammatory challenge, on gene
expression in the well-differentiated HBE cultures. RNA was
harvested from cultures at various times after designated
treatments and hybridized to the Affymetrix U133 Plus 2.0
microarrays. The specific treatments utilized in this study are
depicted in Table 1. Although not all possible PBS controls were
included in the study (e.g., 72 hr PBS), it was recognized that gene
expression could change across time and culture conditions.
Therefore, we were careful to do direct comparisons of treatments
in subsequent analyses only between treatments harvested under
the same culture conditions and culture times. Several different
methods were used to comprehend and interpret the gene
expression responses.
The number of differentially-regulated probesets reveals
AZT-dependent alterations in gene expression
Table 2 summarizes the number of differentially expressed
probesets for the key comparisons as defined by the LPE z-score
,0.05. Using this criterion, AZT alone at 24 hr exposure led to
differential expression of 468 genes, with a fairly equal
representation of up- versus down-regulation, demonstrating the
ability of AZT to alter cellular gene expression in the absence of
any additional treatment. As expected, SMM, which includes a
complex mixture of stimulatory infectious and inflammatory
factors, led to the up-regulation of a large number of mRNA
sequences, with fewer down-regulated probesets, at both 6 and
24 hrs. Importantly, when gene expression was compared between
SMM-exposed cultures with or without AZT pretreatment (last
two rows of Table 2), a large number of gene expression changes
could be identified (649 for 6 hr SMM exposure and 475 for 24 hr
SMM exposure). These results demonstrated that AZT pretreat-
ment significantly altered the way in which HBE responded to the
inflammatory SMM stimulus. AZT affected gene expression after
SMM treatment in both directions, with down-regulation being
the stronger trend. The complete lists of differentially regulated
genes, as defined by our criteria, are provided in Supporting
Information, Table S2.
Hierarchical clustering reveals complexity among the
AZT effects in the presence and absence of inflammatory
stimulus
Clustering of the expression data using the methods described
revealed a complex pattern of gene expression changes (Fig. 1).
The overall trends that could be derived from the cluster analysis
can be summarized as follows:
Baseline gene expression. By comparing T0 to the two
controls, PBS 6 and PBS 24, it can be appreciated that time of
harvest has a measurable effect on global gene expression. While
PBS 24 is distinctly similar to T0, PBS 6 is clearly separated. This
finding suggests that time after media change during standard
culture conditions (6 vs. 24 hr) can affect baseline gene expression
values, likely related to alterations in media components over time
or diurnal variations. These findings highlight the importance of
using controls harvested at the same time during the experiment
for the individual treatment comparisons, rather than comparing
all treatments to T0, which could lead to false conclusions about
treatment effects. All results reported in this study utilize
comparisons with appropriate time-matched controls.
Effect of AZT alone. AZT alone significantly altered global
gene expression at exposures .6 hrs. The close relationship
Table 2. Number of differentially expressed probesets in
selected paired comparisons.
Pair Comparison
Up-
regulated
Down-
regulated Total
AZT 24 hr vs PBS 24 hr 238 230 468
SMM 6 hr vs PBS 6 hr 638 110 748
SMM 24 hr vs PBS 24 hr 562 221 783
AZT 48 hr (+SMM 6 hr) vs. SMM 6 hr 303 346 649
AZT 72 hr (+SMM 24 hr) vs. SMM 24 hr 183 292 475
Table represents the number of significant probesets with LPE z.pv,0.05. A list
of all differentially-regulated probesets is found in Supporting Information,
Table S2.
doi:10.1371/journal.pone.0005806.t002
Azithromycin and Airways
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expression differences between these two treatments. In contrast,
AZT treatments for 24 and 48 hrs are clearly distinct from PBS
24 hrs. Most AZT-induced gene expression changes occurred by
24 hours as indicated by the close relationship of AZT 24 to AZT
48, although the degree of induction of some up-regulated genes
appears to be greater as exposure time is increased (more intense
red in AZT 48 hr as compared to AZT 24 hr).
Effect of SMM. SMM treatment alters the global gene
expression more extensively than AZT, as indicated by all SMM
treatments (regardless of AZT pretreatment) clustering together.
This result points to the expected ability of the inflammatory
SMM treatment to alter global gene expression.
Effect of AZT on SMM. Interestingly, AZT pretreatment,
although clearly unable to prevent the strong SMM-induced effect,
resulted in noticeable alterations in SMM-induced expression, and
close evaluation indicates changes in both directions.
Overall, the ability to detect gene expression differences induced
by AZT in both SMM treated and untreated cultures (Table 2),
coupled with the complex patterns indicated by the cluster analysis
(Fig. 1), led us to seek an understanding of the specific genes/gene
families that were altered among relevant treatment/control pairs.
Gene Ontology (GO) analyses reveal significant trends
We identified GO groups whose gene expression patterns were
significantly different among treatments. Figure 2 summarizes the
findingsbyindicatingallofthemosthighlysignificantGOgroupsfor
the selected treatment pair comparisons (hypergeometric probability
,10
27). Both up-regulated (red) and down-regulated (green) GO
annotation groups are listed. This summary revealed three major
biologically relevant groupings of GO annotations associated with
differential expression among treatment pairs (groupings determined
subjectively): 1) inflammatory/immune responses, 2) lipid/fatty
acid/cholesterol metabolism, and 3) cell cycle/mitosis. Each one of
the major groupings will be discussed in brief separately, followed by
a more detailed analysis of the findings.
Inflammation/immune response genes. As expected, the
inflammation/immune response genes were very significantly up-
regulated by SMM treatment (Fig. 2). The GO groups can be
roughly divided into those that are up-regulated by 6 hrs (e.g.,
chemotaxis and anti-apoptosis) and those not up-regulated until
24 hr (e.g., antigen processing). AZT alone showed no evidence of
significantly affecting these pathways in a global way, with only the
cell-cell signaling module showing significant effects, and then only
at 6 hrs. Additionally, AZT did not significantly alter the global
response of genes in these pathways after exposure to SMM, as
indicated by lack of significance in the AZT+SMM vs. SMM
columns. Thus, it seemed from the GO analyses as if the cells were
able to mount a global inflammatory response to SMM, even in
the presence of AZT.
Genes involved in lipid/fatty acid/cholesterol metabo-
lism. Various GO classes associated with lipid/fatty acid/
Figure 1. Clustering of the expression data. Clustering of the data, as described in Methods, revealing the general organization of differential
gene expression. Green color represents reduced gene expression relative to red color, which represents increased expression. Treatments are
explained in Table 1. PBS: phosphate buffered saline. AZT: azithromycin. SMM: Supernatant of mucopurulent material from CF airways.
doi:10.1371/journal.pone.0005806.g001
Azithromycin and Airways
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SMM after 24 hrs (Fig. 2). Interestingly, despite the fact that the
SMM treatment alone could up-regulate genes in these pathways,
these GO categories were potentiated by the AZT pretreatment, i.e.,
theyare significantlyup-regulated inSMM-exposed HBE pretreated
with AZT as compared with SMM alone. This can be clearly
appreciated in Fig. 2 as consistent up-regulation of many of these
GO groupings in the AZT+SMM vs SMM columns.
Genes involved in cell cycle/mitosis. Genes that fell
within GO groups related to DNA replication, cell cycle, and
mitosis tended to be significantly down-regulated by AZT
treatment. As with the lipid/fatty acid/cholesterol GO
categories, this effect of AZT alone was also seen in cells treated
with SMM, as indicated by significant down-regulation of these
GO groups in the AZT+SMM vs SMM columns (Fig. 2).
Detailed analyses of specific genes within significant GO
categories
Inflammation/immune response genes. As shown in
Fig. 2, there was little indication from the global analysis of
mRNA expression data that AZT pretreatment led to across-the-
board alterations in gene expression of classic immune/
inflammatory response genes. However, our interest in the
inflammatory response of AZT and the extensive literature
linking AZT to inflammatory processes in the lung prompted a
closer evaluation of the effect of AZT treatment on specific
mRNAs with predicted inflammatory/immune functions. To
accomplish this, we looked specifically at the differentially
regulated genes in our study (pulled from the probesets
described in Table 2 and given in Supporting Information,
Table S2) that were annotated in various GO categories known to
be affected by inflammatory stimuli (see caption to Table 3). The
results of these efforts are shown in Tables 3–5, Fig. 3, and Online
Supporting Information, Table S3.
In contrast to the global analyses described above, careful
examination of specific, selected annotation groups indicated that
the genes differentially regulated by AZT did, in fact, tend to
encompass those with inflammatory-related annotations. This is
reflected by the high percentage of all significantly up- or down-
regulated genes that carry inflammatory-related annotations, with
Figure 2. Illustration of the most significant gene ontology (GO) groups whose expression was modulated by the various
treatments. The following comparisons were analyzed: AZT 6 hr vs. PBS 6 hr, AZT 24 hr vs. PBS 24 hr, SMM 6 hr vs. PBS 6 hr, SMM 24 hr vs. PBS
24 hr, AZT 48 hr (+SMM during last 6 hr) vs. SMM 6 hr, and AZT 72 hr (+SMM during the last 24 hr) vs. SMM 24 hr. Green=down-regulated groups;
red=up-regulated groups; white=not significant. Values in boxes represent the probability that the genes within the list from each GO group would
be present by chance – the more negative, the less likely genes within these categories are present by chance. See corresponding text for details.
doi:10.1371/journal.pone.0005806.g002
Table 3. Differential regulation of genes annotated in inflammatory/immune/defense*-related pathways as a function of
treatment group.
Treatment Comparison
Total number of
DR* genes
Number of
DR IID* genes
Percent of all DR genes
identified as IID*
A Z T6h rv sP B S6h r 5 8 2 5 Total 53%
Up-regulated 33%
Down-regulated 20%
AZT 24 hr vs PBS 24 hr 116 85 Total 73%
Up-regulated 34%
Down-regulated 39%
SMM 6 hr vs PBS 6 hr 345 211 Total 61%
Up-regulated 45%
Down-regulated 16%
SMM 24 hr vs PBS 24 hr 297 193 Total 65%
Up-regulated 46%
Down-regulated 19%
AZT 48 hr (+SMM 6 hr) vs SMM 6 hr 205 135 Total 66%
Up-regulated 31%
Down-regulated 35%
AZT 72 hr (+SMM 24 hr) vs SMM 24 hr 143 110 Total 77%
Up-regulated 45%
Down-regulated 32%
*IID=inflammatory/immune/defense related genes. DR=differentially-regulated. Genes were entered into this table as inflammation-related if the z.pv was significant
(,0.05) and if the Gene Ontology classifications contained one or more of the following: cell adhesion, proteolysis, MAPK or MAPKKK, inflammatory/defense/immune/
acute-phase response, apoptosis/cell death, protein transport, cytokine activity, nitric oxide, NF-kappaB, antimicrobial humoral response, unfolded protein,
phagocytosis, B cell activation, lymphocyte proliferation, protein transport/secretion/folding. Note: This table reflects genes, not probesets; thus, the numbers differ
from Table 2. Some of the significant genes are represented by multiple significant probesets. Genes not annotated as inflammation-related are either unannotated or
had Gene Ontology classifications that do not contain the annotations listed above. This table does not include differentially expressed genes in the cholesterol/fatty
acid metabolic pathways or the cell cycle/mitosis/cell division pathways that are discussed in detail elsewhere in the manuscript. The table represents data from a total
of 395 inflammation-related genes that were found to be differentially-regulated based upon our established criteria.
doi:10.1371/journal.pone.0005806.t003
Azithromycin and Airways
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than would be expected by chance for the relatively small number
of selected annotation groups (total number of annotation
groups=20). Enrichment of inflammation-related annotations
was expected with SMM-treated cultures, since SMM is a potent
inflammatory stimulus, but it was also seen with AZT treatment,
both in the presence and absence of SMM. Thus, genes regulated
by both SMM and AZT fall to a significant degree into
inflammatory-type pathways, despite the lack of significance when
analyzed by GO classification.
As predicted, SMM at both 6 and 24 hrs was a stronger
inflammatory stimulus than AZT, as indicated by the larger
number of inflammatory-related genes that were altered in
expression after the SMM treatment as compared with the AZT
treatment (Table 3). As expected, most of these inflammatory-
related genes after SMM treatment were up-regulated (94.4 and
88% for 6 and 24 hr, respectively; Table 4). In contrast, only 46%
of the inflammatory-related genes affected by AZT were up-
regulated after 24 hrs, with the rest being down-regulated. This
same trend for AZT toward down-regulation of inflammatory
genes was evident when AZT treatment preceded the exposure of
HBE to SMM. In these comparisons, 58% of inflammation-related
genes that were differentially expressed between SMM-treated
cultures and SMM-treated cultures pretreated with AZT were in
the down-regulated category (Table 4; last column).
We next used Venn diagrams, which help to visualize the
commonality of differential expression between different treatment
pairs, to comprehend whether or not the inflammatory genes
induced by AZT were the same genes as those induced by SMM.
We found that only 24 (9%; n=24) of genes up-regulated by 6 or
24 hr SMM treatment were also up-regulated by AZT treatment
(Fig. 3, upper Venn diagram, left). These same 24 genes
Figure 3. Venn diagrams representing the number of differentially expressed inflammation-related genes as a function of
treatment. The top Venn diagram compares SMM-induced genes to AZT up- and down-regulated genes. The bottom Venn diagram shows how AZT
pretreatment affected SMM genes.
doi:10.1371/journal.pone.0005806.g003
Table 4. Inflammation-related genes classified as up- or
down-regulated as a function of treatment comparison.
Treatment Comparison Category Number Percent
AZT 6 hr vs PBS 6 hr Up-regulated 19 76%
Down-regulated 6 24%
AZT 24 hr vs PBS 24 hr Up-regulated 40 46%
Down-regulated 45 54%
SMM 6 hr vs PBS 6 hr Up-regulated 199 94%
Down-regulated 12 6%
SMM 24 hr vs PBS 24 hr Up-regulated 170 88%
Down-regulated 23 12%
AZT 48 hr (+SMM 6 hr) vs SMM 6 hr Up-regulated 56 42%
Down-regulated 79 58%
AZT 72 hr (+SMM 24 hr) vs SMM 24 hr Up-regulated 46 42%
Down-regulated 64 58%
*See Table 3 for information concerning the selection of these genes as
inflammation-related. ‘‘Percent’’ in this table represents the percentage of
these inflammation-related genes that are either up- or down-regulated
(category).
doi:10.1371/journal.pone.0005806.t004
Azithromycin and Airways
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glance, this might suggest a tendency for AZT treatment to
stimulate production of inflammatory-related genes that are also
induced by SMM, but with SMM being a much stronger stimulus.
However, a similar number of SMM-induced inflammatory-
related genes (9%) was also down-regulated by AZT treatment
(Fig. 3, upper Venn diagram, right).
AZT pretreatment also affected SMM-induced inflammatory
genes (Fig. 3, bottom Venn diagram). Nearly 24% (n=63) of all
genes normally up-regulated by SMM at either 6 or 24 hrs were
significantly attenuated in expression by either one or both of the
AZT pretreatments (left), suggesting that AZT can dampen the
ability of SMM to induce these genes. Only 9.8% (n=26) of the
same genes were increased in expression by AZT pretreatment
(right). While the qualitative and quantitative characteristics of
these up- and down-regulated genes are likely to be important, as
discussed below, the overall trend was towards a more anti-
inflammatory effect of AZT.
Because AZT could affect genes annotated in inflammatory
categories in either direction, it became important to look
specifically at the genes involved. Table 5 shows the differential
regulation for a selected series of these genes (all inflammatory-
related genes are shown in Supporting Information, Table S3). As
expected, cytokines and chemokines were up-regulated by SMM,
but the effect of AZT on these genes was variable and
inconclusive. IL-8, which has been previously shown to be either
up- or down-regulated by AZT [30–33] was significantly increased
only after short term exposure to AZT alone, and AZT did not
potentiate gene expression of IL-8 in the presence of SMM
exposure (Table 5).
In contrast to cytokines, some genes stimulated by SMM were
attenuated by exposure to AZT (Table 6; Supporting Information,
Table S3). Of particular interest, both MUC5AC and MMP9
expression levels were significantly reduced by AZT, confirming
previous findings with other macrolides [19–22]. In fact, for these
two genes, pretreatment with AZT completely prevented the
normally expected up-regulation by SMM and estimated gene
expression values were reduced to baseline values or below (not
shown). Interestingly, while MUC5AC was the only mucin gene
significantly altered by AZT exposure, several MMPs (MMP1, 2,
10, 13, and 28) in addition to MMP9 tended to be down-regulated
by AZT. The same general pattern of attenuation by AZT was
noticed for SERPIN genes.
Other inflammation-related genes were specifically up-regulated
by AZT. These genes included MHC Class II genes, genes
involved in iron metabolism (ferritin, transferrin receptor), hypoxia
responses (HIF1A, VEGFA), and several others (Table 5).
Plasminogen activator (PLAT) was an additional gene of interest
whose expression was attenuated by AZT, but its sister gene,
PLAU, was potentiated by AZT.
Table 5. Response of cytokine/chemokine genes and their receptors for the selected treatment pairs.
Gene Name Gene Symbol
AZT 6 vs
PBS6
AZT24 vs
PBS24
SMM6 vs
PBS6
SMM24 vs
PBS24
AZT48 SMM6
vs SMM6
AZT72 SMM24
vs SMM24
chemokine (C-X-C motif) ligand 1 CXCL1 UP UP
chemokine (C-X-C motif) ligand 14 CXCL14 DOWN
chemokine (C-X-C motif) ligand 16 CXCL16 UP
chemokine (C-X-C motif) ligand 2 CXCL2 UP UP
chemokine (C-X-C motif) ligand 3 CXCL3 DOWN UP UP DOWN
chemokine (C-X-C motif) ligand 5 CXCL5 UP UP
chemokine (C-X-C motif) ligand 6 CXCL6 DOWN UP UP DOWN
chemokine (C-X-C motif) receptor 7 CXCR7 UP UP
interleukin 13 receptor, alpha 1 IL13RA1 UP
interleukin 17C IL17C UP
interleukin 19 IL19 UP
interleukin 1, alpha IL1A UP UP DOWN UP
interleukin 1, beta IL1B UP
interleukin 1 family, member 9 IL1F9 UP UP
interleukin 1 receptor-like 1 IL1RL1 DOWN
interleukin 1 receptor antagonist IL1RN UP UP UP UP
interleukin 32 IL32 UP UP
interleukin 4 receptor IL4R UP UP
interleukin 6 (interferon, beta 2) IL6 UP UP UP
interleukin 6 signal transducer IL6ST UP UP UP UP
interleukin 7 IL7 DOWN DOWN
interleukin 8 IL8 UP UP UP
The direction of differential regulation is given by UP or DOWN, indicating the direction that gene expression moved in the treatment (listed first) vs. the control (listed
last). Genes are only considered differentially-regulated if the LPE z.pv,0.05 as determined as described in Methods. Only genes with significant findings for at least one
of the comparisons are shown (genes in the same categories that were not affected by any of the treatments are not shown). This Table is a subset of Table S3 from
Supporting Information, which lists all genes with inflammatory annotations. Blank cells indicate that the gene was not-differentially-regulated for that particular
treatment comparison.
doi:10.1371/journal.pone.0005806.t005
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The striking up-regulation of these pathways by AZT after
24 hrs represents a novel finding. A detailed view of genes in these
GO categories that were significantly affected by the treatments in
this study is provided in the Supporting Information, Table S4. It
can be appreciated that both lipid/fatty acid/cholesterol meta-
Table 6. Response of selected classes of inflammation-related genes across selected treatment pairs.
Gene Class and Response/Gene Name
Gene
Symbol
AZT 6 vs
PBS6
AZT24 vs
PBS24
SMM6 vs
PBS6
SMM24 vs
PBS24
AZT48 SMM6
vs SMM6
AZT72 SMM24
vs SMM24
MHC Class II complex genes: Up-regulated by SMM:
potentiated by AZT
major histocompatibility complex, class II, DP beta 1 HLA-DPB1 UP
major histocompatibility complex, class II, DQ alpha 1 HLA-DQA1 DOWN UP UP
major histocompatibility complex, class II, DQ beta 1 HLA-DQB1 UP UP UP UP
major histocompatibility complex, class II, DR alpha HLA-DRA UP UP
major histocompatibility complex, class II, DR beta 1 HLA-DRB1 UP UP UP
Matrix metalloproteinases: tend to be up-regulated
by SMM treatment, down-regulated by AZT
matrix metallopeptidase 1 MMP1 DOWN UP DOWN
matrix metallopeptidase 2 MMP2 DOWN
matrix metallopeptidase 9 MMP9 DOWN UP DOWN DOWN
matrix metallopeptidase 10 MMP10 DOWN UP UP DOWN DOWN
matrix metallopeptidase 13 MMP13 DOWN UP UP DOWN DOWN
matrix metallopeptidase 14 MMP14 UP
matrix metallopeptidase 28 MMP28 UP DOWN
SERPIN genes: tend to be upregulated by SMM;
attenuated by AZT
serpin peptidase inhibitor, clade A, member 1 SERPINA1 UP
serpin peptidase inhibitor, clade A, member 3 SERPINA3 UP UP UP
serpin peptidase inhibitor, clade B, member 1 SERPINB1 UP UP DOWN DOWN
serpin peptidase inhibitor, clade B, member 2 SERPINB2 DOWN DOWN DOWN
serpin peptidase inhibitor, clade B, member 4 SERPINB4 UP UP
serpin peptidase inhibitor, clade B, member 9 SERPINB9 UP UP DOWN
serpin peptidase inhibitor, clade E, member 1 SERPINE1 UP UP DOWN
Mucins: Response variable: Up-regulated by SMM;
strong inhibition of MUC5AC by AZT
mucin 5AC MUC5AC UP UP DOWN DOWN
mucin 5B MUC5B UP
mucin 1 MUC1 UP
mucin 4 MUC4 UP
mucin 13 MUC13 UP
Miscellaneous genes; Generally upregulated by SMM;
Mostly potentiated or by AZT
dual specificity phosphatase 5 DUSP5 UP UP UP UP
lymphocyte antigen 96 LY96 UP UP UP UP UP
transferrin receptor (p90, CD71) TFRC UP UP UP UP
ferritin, heavy polypeptide 1 FTH1 UP UP
ferritin, light polypeptide FTL UP UP UP
growth differentiation factor 15 GDF15 UP UP UP UP UP
hypoxia-inducible factor 1, alpha subunit HIF1A UP UP
vascular endothelial growth factor A VEGFA UP UP UP
plasminogen activator, tissue PLAT DOWN UP UP DOWN DOWN
plasminogen activator, urokinase PLAU UP UP UP
The direction of differential regulation is given by UP or DOWN, indicating the direction that gene expression moved in the treatment (listed first) vs. the control (listed last).
Genes are only considered differentially-regulated if the LPE z.pv ,0.05 as determined as described in Methods. Only genes with significant findings for at least one of the
comparisons are shown (genes in the same categories that were not affected by any of the treatments are not shown). This Table is a subset of Table S3 from Supporting
Information, which lists all genes with inflammatory annotations. Blank cells indicate that the gene was not-differentially-regulated for that particular treatment comparison.
doi:10.1371/journal.pone.0005806.t006
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transport are affected by AZT. A specific analysis of a subset of
these genes, the cholesterol biosynthetic pathway, as viewed
schematically in Figure 4A, provides further confirmation of the
findings. Many of the genes up-regulated by AZT were also up-
regulated by SMM, and the results suggest an additive effect, since
many of the genes were highest in expression in the presence of
both SMM and AZT (Supporting Information, Table S4).
Of particular interest in this group was the up-regulation of
SREBP1 (sterol regulatory element binding protein 1. SREBP1,
and its counterpart SREBP2, are structurally related proteins that
control cholesterol homeostasis by stimulating transcription of
sterol-regulated genes containing the sterol regulatory element.
Up-regulation of this transcription factor alone could, at least in
part, explain the up-regulation of many of the other genes in this
pathway, a finding that was illustrated in a schematic view of the
most significant pathways altered by 24 hr AZT treatment as
determined by Ingenuity Pathway Analysis
TM software (Figure 4B).
Additionally, a second master regulator of cholesterol homeostasis,
insulin-induced gene-1 (INSIG-1), which is a critical component of
the sterol-sensing pathway due to its modulation of SREBP
processing that prevents SREBP1 activation [34], was also
significantly up-regulated by the AZT treatment (Supporting
Information, Table S4), suggesting that the cells were attempting
to reestablish equilibrium.
Cell Cycle/Mitosis Genes
The gene expression values of the cell cycle/mitosis genes,
including genes for DNA replication and chromosome segrega-
tion, were down-regulated by AZT treatment, mainly when AZT
was present for more than 6 hours (Supporting Information, Table
S5). Interestingly, upon more careful evaluation, many of these
same genes (43%) having the cell cycle/mitosis annotations that
were down-regulated by AZT at 24 hr were also significantly
down-regulated by 24 hr SMM treatment, although the signifi-
cance of the down-regulation after the SMM treatment was not as
Figure 4. AZT up-regulates lipid/cholesterol metabolism and down-regulates cell cycle genes. A: The cholesterol biosynthetic pathway
and the fold-changes induced for each of the enzymes within the pathway are indicated. Data are expressed as fold changes in gene expression
values from 24 hr AZT vs. 24 hr PBS (left numbers), 24 hr SMM vs. 24 hr PBS (center numbers) and 72 hr AZT (+addition of mucosal SMM during the
last 24 hr) vs. 24 hr PBS (right numbers). Both SMM and AZT increased the enzymes involved in the cholesterol biosynthetic pathway, and their effect
appears to be additive. B and C: Ingenuity Pathways Analysis
TM was used to generate two top significant networks for genes regulated by AZT 24 hr
vs. PBS 24 hr. The top two networks are shown. The analysis settings were as follows: only direct relationships were considered, endogenous
chemicals were excluded, and only relationships where data sources=Argonaute 2 or Ingenuity curated findings were considered. The network
depicted in B was labeled ‘‘Lipid Metabolism, Small Molecule Biochemistry, Nucleic Acid Metabolism’’ and had a score=47. The network depicted in C
was labeled ‘‘Cancer, Cell Cycle, Reproductive System Disease’’ and had a score=44. Red indicates up-regulation. Green indicates down-regulation.
doi:10.1371/journal.pone.0005806.g004
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significant findings for SMM treatments in Fig. 1. The effect of
AZT after 24 hrs on these genes could be visualized schematically
utilizing the Ingenuity Pathways Analysis
TM output (Figure 4B).
For the second most highly significant network, nearly all of the
genes represented as green (down-regulated) were found in the
GO categories highlighted in Supporting Information, Table S5.
Confirmatory Studies
To confirm and/or extend some of the major findings in the
microarray studies, we have analyzed three specific components:
MUC5AC expression, IL-8 secretion, and cholesterol metabolism.
A brief summary of these results follows.
AZT inhibits basal and SMM-stimulated mucin
production. The inhibitory effect of AZT on MUC5AC gene
expression seen on the microarrays was reproduced by
quantitative real-time PCR studies (Fig. 5A). To confirm that
the inhibitory effect of AZT was coupled to a decreased MUC5AC
protein expression, immunocytochemical analysis for MUC5AC
was performed. It was found that AZT decreased MUC5AC
protein expression levels from both PBS- and SMM-exposed
cultures (Fig. 5B). A similar effect of AZT on total mucin protein
expression was observed in HBE subjected to the same
experimental protocol and stained with Alcian blue/periodic
acid-Schiff (AB/PAS; Fig. 5C). AB/PAS stains carbohydrates and
reveals mucin-secreting cells, since ,90% of the mucin weight is
derived from glycans. Thus, in the case of MUC5AC, the
microarray data were corroborated by protein expression analyses.
Azithromycin pretreatment increases IL-8 release after
inflammatory challenge. As determined by microarrays, IL-8
levels were not dramatically affected and these results were
confirmed by real-time PCR analysis (data not shown). However,
because of the reported alterations in IL-8 levels after AZT
treatment [31], we evaluated whether IL-8 secretion correlated
with the mRNA findings. To begin these studies, IL-8 protein
levels were measured in the presence or absence of AZT as
described in methods. Figure 6A illustrates that none of the AZT
doses had any significant effect on the basal IL-8 secretion,
regardless of the duration of exposure, consistent with the
microarray results. Surprisingly, however, additional studies
using SMM to stimulate IL-8 levels showed that AZT enhanced
SMM-induced IL-8 secretion, an effect that was apparent at 1 mg/
ml AZT and reached a maximum at 10 mg/ml AZT (Fig. 6B).
To further characterize this response, longer time courses were
performed in HBE exposed to a maximal dose of 100 mg/ml AZT
for up to 96 hrs, and IL-8 secretory responses in the absence or
presence of SMM were evaluated. AZT again had no effect on
basal levels of secreted IL-8 at 24 or 48 hr (Fig. 6C). IL-8 secretion
triggered by 24 or 48 hr SMM exposure was potentiated by
pretreatment with AZT (Fig. 6C). Thus, in contrast to the
microarray data (Table 5), which showed no effect of AZT
pretreatment on IL-8 at the mRNA level, AZT pretreatment,
surprisingly, altered IL-8 protein levels. These findings highlight
additional complexities involved in evaluating the inflammatory
effects of macrolides and in using microarray data to evaluate an
inflammatory state.
Cholesterol metabolic pathway. The microarray results
illustrating the up-regulating effect of AZT on the cholesterol
metabolic pathway (Fig. 4A) were confirmed using RT-PCR for
SREBP1 on a separated set of HBE cultures. These studies
demonstrated that the master regulator of cholesterol biosynthesis
was up-regulated by AZT (Fig. 7A). To address whether the up-
regulation of SREBP1 and cholesterol biosynthetic genes by either
AZT or SMM resulted in an increased cholesterol accumulation,
HBE were exposed for 24 hr to 1) mucosal PBS, 2) 30 mg/ml
serosal AZT, 3) mucosal SMM, or 72 hr 30 mg/ml serosal AZT
Figure 5. AZT decreases basal and SMM-stimulated mRNA and protein expression levels of MUC5AC in human airway epithelia.
Well-differentiated HBE were exposed for 24 hr to mucosal PBS or mucosal SMM in the absence of presence of 72 hr pretreatment with 30 mg/ml
serosal AZT. A: MUC5AC mRNA levels, expressed as fold change from mucosal PBS-exposed HBE. B: Immunocytochemical assessment of MUC5AC in
HBE. Right panel depicts compiled data from MUC5AC expression as a percent of PBS-exposed HBE. C: AB-PAS staining from HBE subjected to the
various treatments. Right panel shows compiled data from AB-PAS staining as a percent of PBS-exposed HBE. *p,0.05 vs. PBS-exposed HBE; #
p,0.05 SMM+AZT-exposed HBE vs. SMM-exposed HBE.
doi:10.1371/journal.pone.0005806.g005
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staining with filipin to visualize free cholesterol. As depicted in
Fig. 7B, filipin fluorescence was equally increased by AZT or
SMM exposure in HBE (Figs. 7B-II and 7B-III), as compared with
PBS-exposed epithelia (Fig. 7B-I). To confirm that AZT- or SMM-
increased filipin fluorescence resulted from cholesterol
biosynthesis, cultures were pretreated with 50 mM mevastatin to
inhibit the activity of 3-hydroxy-3-methylglutaryl-CoA reductase.
Mevastatin pretreatment blocked the effect of AZT or SMM on
filipin fluorescence (Figs. 7B-V and 7B-VI), confirming that
exposure of HBE to AZT or SMM increases cholesterol
biosynthesis. The compiled data from filipin fluorescence
intensity from all conditions are depicted in Fig. 7C. Exposure
of HBE to both AZT and SMM did not further increase filipin
fluorescence as compared to filipin fluorescence from HBE
exposed to AZT or SMM alone (data not shown).
We then considered whether the increase in cholesterol
biosynthesis was linked to the increased IL-8 secretion shown in
Fig. 6. To address this question, IL-8 secretory responses were
investigated in HBE individually exposed to PBS, AZT or SMM
or HBE exposed to both AZT+SMM in the absence or presence of
mevastatin. Although mevastatin decreased AZT- or SMM-
induced cholesterol accumulation in HBE (Figs. 7B and 7C), it
did not affect SMM-induced IL-8 secretion or decreased AZT-
potentiated SMM-dependent IL-8 secretion (Fig. 7D). These
findings suggest that there is no link between cholesterol
accumulation resulting from AZT or SMM and IL-8 secretion.
These results also suggest that the potentiating effect of AZT on
SMM-induced IL-8 secretory responses (Fig. 6) is not mediated by
increases in cholesterol biosynthesis.
Discussion
The reported effects of macrolides on inflammatory responses
have recently been reviewed [3]. They include suppression of
production and secretion of pro-inflammatory cytokines, suppres-
sion of inducible nitric oxide (NO) synthase-mediated NO
production, decreased mucus synthesis and secretion, promotion
of inflammatory cell apoptosis, decrease in production of nuclear
transcription factors, inhibition of chloride and water secretion
across airways, and interruption of bacterial virulence [3]. In our
studies, the combined data, primarily obtained from RNA
microarrays using a relevant model of well-differentiated primary
airway epithelial culture, demonstrate that the macrolide antibiotic
AZT affected the expression of genes predominantly in three
major categories: inflammation/immune response (variable re-
sponse, both up and down-regulation), lipid/fatty acid/cholesterol
metabolism (up-regulation), and cell cycle/mitosis (down-regula-
tion). Whereas the effect on inflammation/immune responses and
cell cycle/mitosis genes may have been predicted from previous
work, the strong effect on lipid metabolism genes is a novel finding.
Our analyses of expression for genes annotated in inflamma-
tory/immune pathways after AZT treatment point to complex and
gene-specific effects. Unlike the inflammatory stimulus SMM,
which primarily increased the expression of genes annotated in
inflammatory-related pathways, AZT differentially regulated
inflammatory-related genes in both directions (up and down),
with a trend toward down-regulation based upon numbers (Fig. 3
and Tables 3 and 4). This finding is significant because it suggests
that the induction of at least some inflammatory genes normally
strongly up-regulated by SMM was reduced by the AZT
pretreatment. It also helps explain why the AZT effect was not
evident in the global analyses, because a dilution of GO
annotations into both up- and down-regulated categories would
tend to lower the significance of each effect individually. AZT did
not have a consistent effect on cytokine/chemokine expression
(Table 5), which suggests that classic mechanisms leading to up-
regulation of cytokines/chemokines in airway epithelial cells, such
as activation of the NF-kappaB-mediated pathways, are, for the
most part, unaffected by AZT. Nevertheless, AZT had significant
effects on other highly relevant genes known to be involved in
airway biology during the course of inflammatory disease. Overall,
the microarray data provides a very complex picture of the effect
of AZT on inflammatory-related genes, and it is likely that the
individual gene effects, such as down-regulation of MUC5AC and
MMP9, may be more important to the final inflammatory
outcome than the overall global response might predict. The
results are consistent with the literature findings suggesting that
AZT can display anti-inflammatory properties at the same time
that some inflammatory processes seem to be up-regulated.
Our microarray studies (Table 6) have confirmed and extended
previous findings showing decreased gene expression of MUC5AC
Figure 6. Effect of AZT on IL-8 secretion in human airway epithelia. A: AZT does not affect basal airway epithelial IL-8 secretion. Basal IL-8
secretion from well-differentiated primary cultures of normal human bronchial epithelia serosally exposed to different doses of AZT for 24 hr and
48 hr. B: Dose response for AZT-potentiated IL-8 secretion triggered by 24 hr mucosal exposure of HBE to supernatant from mucopurulent material
(SMM) from CF airways. Well-differentiated primary cultures of normal human bronchial epithelia were pretreated with AZT for 72 hr and exposed to
mucosal PBS or SMM during the last 24 hr of macrolide treatment. C: Time course for AZT-potentiated SMM-induced IL-8 secretion. Vehicle or
100 mg/ml AZT were added to the serosal surface of well-differentiated normal HBE and a 48 hr time course performed for IL-8 secretion. AZT
pretreatment did not alter the basal levels of secreted IL-8, but potentiated SMM-induced IL-8 secretion at both 24 and 48 hr (corresponding to 72
and 96 hr AZT treatment, respectively).
doi:10.1371/journal.pone.0005806.g006
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observations, inhibitory effects of macrolides on inflammatory
mediators were observed in the presence of inflammatory stimuli,
such as lipopolysaccharide [19–22,35,36]. The inhibitory effect of
AZT on MUC5AC gene expression in the present study was
confirmed at the protein level (Fig. 5). This finding may explain
the link between macrolide use and decreased mucus secretion in a
variety of chronic airway diseases [37].
In addition to MMP9, our studies revealed that other MMP
proteins (e.g., MMP1, 10, and 13) were also inhibited by AZT
(Table 5). MMP9, which is involved in the degradation of
extracellular matrix components, was reported to mediate N-
terminal cleavage of IL-8, to potentiate IL-8 activation of
neutrophils [38], and to cleave and activate latent TGF-b2 [39].
Increased concentrations of MMP9 in asthmatic and CF patients
as compared to normal subjects [40,41] and in CF patients with
poor lung function [42] have led to the conjecture that MMP9
may contribute to both inflammation and airway remodeling.
Because SERPINB (serine peptidase inhibitor Clade B) genes,
which are also recognized as important mediators of inflammatory
responses in the airway [43], tended to be down-regulated by
AZT, our findings suggest that a common down-regulatory
mechanism for AZT might be shared with MMP and SERPIN
genes (see also Supporting Information, Table S3). The other
observed, specific effects of AZT on expression of other
inflammatory genes, such as up-regulation of HLA, LY96,
GDF15, HIF1A, ferritin and plaminogen activator genes
(Table 6), may also be relevant to airway inflammatory diseases.
Although we did not directly measure MMP9 protein levels or
activity in this study, reduction in MMP9 activity has been
measured in recent reports evaluating macrolide activity in in vivo
systems [44–46]. Specifically, of interest with regards to lung
disease are the findings that MMP9 concentrations were reduced
in sputum from a group of patients with refractory asthma that
were receiving clarithromycin [45].
On the other hand, an important aspect of our studies was the
demonstration that the inflammatory state could not be predicted
from gene expression data alone. This notion was based on the
Figure 7. Mucosal bacterial and inflammatory mediator challenge (SMM) or serosal AZT induces accumulation of cholesterol in
human airway epithelia. A: Quantitative RT-PCR confirmation of increased SREBP1 levels in AZT-treated cultures. B: Representative filipin stain in
WD HBE exposed to 24 hr mucosal PBS (I), 24 hr mucosal SMM (II) or 24 hr 30 mg/ml serosal AZT (III). (IV–VI): Same conditions as in I–III, except that
cultures were pretreated with 50 mM mevastatin, as described in Methods. Bar: 10 mm. C: Compiled data from filipin fluorescence from the treatments
illustrated in 7B. *p,0.05 vs. 24 hr PBS-exposed HBE; # p,0.05 vs. same condition without mevastatin pretreatment. D: IL-8 secretion induced by
SMM or by SMM in presence of AZT is not affected by inhibition of cholesterol biosynthesis. Well-differentiated HBE were exposed for 24 hr to
mucosal PBS, mucosal SMM or 30 mg/ml serosal AZT in the presence or absence of mevastatin, and IL-8 secretory responses measured as described in
Methods. *p,0.05 SMM+AZT- vs. SMM-exposed HBE.
doi:10.1371/journal.pone.0005806.g007
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inflammation, secreted IL-8 protein levels (Fig. 6). Whereas AZT
alone produced no striking effect on secreted IL-8 levels, AZT
pretreatment resulted in an unexpected, but consistent, increase in
the levels of secreted IL-8 after SMM treatment (Figs. 6B and 6C).
This finding is in general agreement with Shinkai et al [31], who
reported that treatment with AZT for 24–48 hrs increased basal
IL-8 release and had an additive effect on LPS-induced IL-8
secretion in normal human bronchial epithelia. In addition, this
observation correlates with short-term clinical studies that suggest
a pro-inflammatory response to AZT [32]. The increased IL-8
protein secretion was not reflected in the mRNA levels, as
determined by microarrays or quantitative PCR. Dissecting out
the mechanism responsible for the disconnect between mRNA and
protein, which likely involves regulation of post-translational
processes and/or IL-8 secretion, will be an important step in
understanding the mechanisms of action of the immunomodula-
tory effects of macrolide therapy.
Unlike genes annotated to inflammation/immune response
pathways, the direction of differential gene expression for
cholesterol/lipid metabolism and cell cycle genes was very clear
(Figs. 2 and 4; Supporting Information, Tables S4 and S5). Lipid/
cholesterol related genes were up-regulated by AZT, which
constitutes a novel finding in airway epithelial cells, whereas cell
cycle genes were down-regulated by the macrolide. Although it is
not clear how these changes could contribute to long-term in vivo
responses, they likely play an important role in the therapeutic
mode of action of macrolides.
Perturbations in lipid/cholesterol metabolism have been associ-
atedwith manydiseases (reviewed in[47,48]),and itiscertainlyclear
that these pathways, and the products produced from them, can
regulate inflammation in both a positive and a negative direction.
The link between macrolide treatment and lipid/cholesterol
pathway gene expression seen in the present study is in agreement
with previous observations demonstrating increased total cell
phospholipids and cholesterol in rat fibroblasts following macrolide
administration [49]. Based on our findings that AZT increases the
expression of SREBP1, an important transcriptional regulator of
lipid/cholesterol homeostasis, we speculate that the up-regulation of
SREBP1 gene expression likely mediates the increased cholesterol
biosynthetic response induced by AZT (Figs. 4 and 7; Supporting
Information, Table S4). In general, cholesterol levels are a critical
determinant of SREBP activation, which involves cleavage of an
endoplasmic reticulum-bound precursor into a nucleus-localized
transcription factor during periods of cholesterol depletion. Once
cholesterol levels normalize, SREBP binds to INSIG, another gene
also found to be up-regulated in this study by AZT, to prevent
further activation. The up-regulation of the SREBP inhibitor INSIG
in our study likely reflects the epithelial need to reestablish
homeostasis. The additive effect of AZT on these pathways in the
presence of SMM suggests that the two treatments activate the
pathways by separate mechanisms. In the presence of SMM, these
pathways are likely up-regulated by a pathway involving ERK1/2
phosphorylation of SREBP [50,51]. Although it is not clear how
AZT might be acting, certain hypothesis can be put forward. In cells
arrested at G2/M, for example, the transcriptional and DNA-
binding activity of SREBP-1 is determined by hyper-phosphoryla-
tion mediatedbyCDK-1/cyclinB[50].Thesepreviousobservations
suggest a possible link between AZT-induced inhibition of cell cycle
genes, an additional finding in the present study (Fig. 2 and
Supporting Information, Table S5), and the lipid/cholesterol
pathways. In addition, AZT and another macrolide, erythromycin,
can directly interact with phospholipids, modify membrane
biophysical properties, and affect membrane dynamics in living cells
[52–54], processes that have been hypothesized account for activity
and/or toxicity. These findings are also likely relevant to the
mechanismbywhichAZTinducesphospholipidosis,awell-described
in vivo effect of AZT [55]. Additionally, given that one essential
function of SREBP appears to be its ability to monitor cell membrane
composition and to adjust lipid synthesis accordingly [56], it is
possible that the interaction of macrolides with the membrane
provides a strong signal to the cell to compensate for membrane
disruptions. Given all of these diverse findings, it is reasonable to
propose a link between the membrane accumulation of AZT, the
induction of phospholipidosis by AZT, the up-regulation of lipid gene
metabolism reported here, and the final clinical outcome.
Finally, down-regulation of mitosis/cell cycle genes by AZT
could also contribute to its therapeutic effects. For example, a
decrease in the proliferation of airway epithelial cells, such as
mucus-producing cells, in response to luminal bacterial and
inflammatory stimuli might result in reduced inflammatory burden
by preventing the expression of these cells. Studies in cancer cells
or virally-transformed cells showed no effect of macrolide
treatment on proliferation, viability or distribution of the cell
cycle phase [57,58]. In contrast, other studies using a cell system
similar to ours, showed that clarithromycin delayed progression of
primary bronchial cells from G1 to S phase [59]. A reduction in
the expression of cell cycle genes was not considered in the latter
study, but a correlation to ERK1/2 activation, a well-established
pathway for controlling the cell cycle, was described [59]. In fact,
regulation of the ERK1/2 signaling pathway has been proposed as
a unifying mechanism explaining the complex immunomodulation
of macrolides (reviewed in [3]). Studies using the macrolide
clarythromycin demonstrated decreased, and then increased,
phosphorylation of ERK in response to a bacterial stimulant,
flagellin, at 9 and 24 hrs, respectively [60]. A similar finding
involving reduction in ERK phosphorylation after LPS stimulation
in the presence of macrolide antibiotics has recently been reported
by a separate group [36], and it has been hypothesized that
reduction in ERK activation could lead to reduced mucin gene
expression. Although our studies did not evaluate ERK phos-
phorylation, they are consistent with this hypothesis. On the other
hand, based upon studies demonstrating increased transcriptional
activation of SREBP-target genes after ERK-mediated phosphor-
ylation of SREBP [50,51], a reduction in ERK phosphorylation
does not help to explain the up-regulation of lipid/fatty acid/
cholesterol metabolic pathways observed in our studies.
In summary, global gene expression data suggest that the
macrolide AZT can alter inflammatory responses as predicted from
clinical observations, but these responses are highly variable and
gene-specific, with an overall tendency toward global down-
regulation. The striking down-regulation of the RNA of specific
genes, e.g., MUC5AC and MMP9, is likely to be highly relevant to
clinical outcomes, and future studies focusing on the role of these
individual effects should help identify the dominant pathways
involved in the clinical actions of AZT. The increased IL-8 protein
secretion afterinflammatorychallenge inthe presenceof AZTpoints
to the complexity of interpreting gene expression data in light of the
inflammatory outcome. The remarkable and highly significant up-
regulation of lipid/cholesterol metabolic pathways and down-
regulation of cell cycle/mitosis genes is worthy of consideration in
future studies evaluating the mode of action of macrolides.
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